Categories Analysis, Technology
Should you buy Oracle (ORCL) stock ahead of next week’s earnings?
The company will publish second-quarter 2023 earnings report on December 12 after the close of regular trading
The cloud infrastructure market in the U.S. is projected to grow by double digits through 2030. The fast-paced cloud adoption has made leading tech firms like Oracle Corporation (NYSE: ORCL) revisit their business models, with extra focus on cloud computing. After successfully transitioning from a software provider into a cloud-centric company, Oracle has been busy aligning its operations with the ongoing digital transformation. However, economic uncertainties have necessitated cost-cutting measures, and the company is reducing its cloud workforce and has imposed a hiring freeze.
The Stock
At its peak, the stock traded close to $100 — more than a year ago — before entering a volatile phase. Encouragingly, the shares have returned to the growth path ahead of next week’s earnings, bringing cheer to shareholders. The momentum will likely be extended into the next year, but those looking to own the stock would be keen to check out the earnings outcome before investing. Analysts are divided in their recommendations for the stock, which looks a bit expensive.
Read management/analysts’ comments on quarterly reports
As far as the management’s growth strategy is concerned, a key development was Oracle’s acquisition of health information technology company Cerner for about $28 billion in the first half. The deal marks the company’s foray into the healthcare market and is expected to give significant mileage to the Cloud business.
Cloud Power
The good news is that Oracle Cloud continues to grow organically, even though the broad tech market is experiencing weakness amid economic headwinds. The company is incorporating advanced AI capabilities into the cloud platform, in association with chipmaker Nvidia Corporation (NASDAQ: NVDA).
From Oracle’s Q1 2023 earnings conference call:
“Customers are already buying applications and cloud infrastructure from several different providers, including Microsoft, Amazon, Salesforce, Oracle, and others. Our job is to give our customers the ability to choose application and infrastructure technology from multiple clouds and then have those different clouds coexist and interoperate gracefully. Multi-cloud interoperability is an important step in the evolution of cloud computing.”
Snowflake appears to be on solid footing despite cloud slowdown
The market will be closely following Oracle’s second-quarter earnings report, which is slated for release on December 12 after the close of regular trading. Market watchers are looking for earnings of $1.18 per share, excluding special items, which represents a year-over-year decline of about 2.5%. The revenue estimate is $12.04 billion.
Financials
In the first quarter, double-digit growth in the core Cloud Services and License Support business drove up total revenues by 18% to $11.5 billion, significantly faster than the 5% growth recorded in the prior quarter. Earnings, adjusted for one-off items, remained unchanged at $1.03 per share. Revenues matched estimates, while the bottom line missed. It is worth noting that quarterly earnings either beat or matched estimates consistently for about five years, through the first half of FY22.
In a sign that the market was not happy with the mixed earnings outcome and the management’s weaker-than-expected second-quarter guidance, the stock slid in the following sessions and slipped to the lowest level in about one-and-half years. But it soon regained strength. ORCL traded lower on Tuesday afternoon, after closing the previous session down 3%.
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on